Does the Trojan horse have an Achilles' heel?
Dougan
Gordon
G
Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, United Kingdom.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D055808:Drug Discovery / Q000266:history; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D054324:Enterohemorrhagic Escherichia coli / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity; D029968:Escherichia coli Proteins / Q000378:metabolism*; D005604:Francisella tularensis / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D049673:History, 20th Century; D012480:Salmonella Infections / Q000188:drug therapy; D012486:Salmonella typhimurium / Q000187:drug effects; D014406:Tularemia / Q000188:drug therapy; D037521:Virulence Factors
D000900:Anti-Bacterial Agents; D029968:Escherichia coli Proteins; C455504:QseC protein, E coli; D037521:Virulence Factors